X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
SEP-363856 (ulotaront) is a TAAR1 agonist with 5-HT1A agonist activity, is currently under investigation for the treatment of schizophrenia, generalized anxiety disorder and the adjunctive treatment of MDD with additional indications under consideration.
Lead Product(s): Ulotaront
Therapeutic Area: Psychiatry/Psychology Product Name: SEP-363856
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Recipient: Sunovion Pharmaceuticals
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 26, 2023
Details:
Brexpiprazole (Rexulti) is an adjunctive therapy to antidepressants in adults with major depressive disorder and as a treatment for schizophrenia in adults and children ages 13 years and older.
Lead Product(s): Brexpiprazole
Therapeutic Area: Psychiatry/Psychology Product Name: Rexulti
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: H. Lundbeck AS
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 01, 2022
Details:
Avanir and Otsuka have always shared a deep commitment to advancing solutions that improve the lives of patients by Nuedexta (dextromethorphan hydrobromide and quinidine sulfate).
Lead Product(s): Deudextromethorphan Hydrobromide,Quinidine sulphate
Therapeutic Area: Neurology Product Name: AVP-786
Highest Development Status: Phase IIIProduct Type: Small molecule
Recipient: AVANIR PHARMS
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Merger October 24, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
